FDA-approved drug helps treat rare immunologic disease, study finds

Adding the injectable drug mepolizumab to standard treatment for eosinophilic granulomatosis with polyangiitis (EGPA), a rare immunologic disease, significantly improved clinical outcomes among participants in an advanced clinical trial, scientists report. …read more

Source: EurekAlert

(Visited 4 times, 1 visits today)

Popular Posts